trending Market Intelligence /marketintelligence/en/news-insights/trending/zC-niy5shgeGK4gdH3QFxw2 content esgSubNav
In This List

US FDA approves Jubilant Life Sciences' generic arthritis drug

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


US FDA approves Jubilant Life Sciences' generic arthritis drug

The U.S. FDA approved Jubilant Life Sciences Ltd.'s celecoxib capsules for the treatment of osteoarthritis and rheumatoid arthritis.

Celecoxib is a generic version of Pfizer Inc. unit G.D. Searle LLC's Celebrex.